Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $23.00

Key Points

• Theravance Biopharma has received a consensus rating of "Buy" from five research firms, with an average 12-month target price of $23.00.
• Significant upgrades have been noted, including Zacks raising the stock from "hold" to "strong-buy" and BTIG increasing its price target from $24.00 to $25.00.
• Insider Rhonda Farnum sold 10,000 shares of the company at $11.39 each, reducing her ownership by 2.97% while institutional investors collectively hold 99.10% of the stock.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $23.00.

A number of equities research analysts recently commented on TBPH shares. Zacks Research cut shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Monday. B. Riley started coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They issued a "buy" rating and a $28.00 price objective on the stock. BTIG Research increased their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research note on Tuesday, June 17th. Finally, Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th.

Theravance Biopharma Trading Up 1.4%

Shares of NASDAQ:TBPH traded up $0.20 on Friday, reaching $14.07. 128,175 shares of the company were exchanged, compared to its average volume of 294,118. Theravance Biopharma has a 1-year low of $7.88 and a 1-year high of $14.55. The firm has a market cap of $708.62 million, a price-to-earnings ratio of 58.68 and a beta of 0.05. The company has a 50-day moving average of $12.51 and a 200-day moving average of $10.67.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president directly owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. Nuveen LLC purchased a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $3,348,000. Jefferies Financial Group Inc. raised its stake in shares of Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock valued at $3,054,000 after purchasing an additional 255,455 shares during the period. Acadian Asset Management LLC raised its stake in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after purchasing an additional 174,451 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Theravance Biopharma by 80.2% during the second quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company's stock valued at $2,264,000 after purchasing an additional 91,341 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Theravance Biopharma by 30.8% during the second quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company's stock valued at $4,274,000 after purchasing an additional 91,300 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.